25-Hydroxyvitamin D response to graded vitamin D₃ supplementation among obese adults
Drincic A, Fuller E, Heaney RP, Armas LA
The Journal of clinical endocrinology and metabolism · 91 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Creighton University
Según 1 financiador declarado.
Publicación
- Publicado
- 2013-09-14 · J Clin Endocrinol Metab · vol. 98 · número 12 · págs. 4845–4851
- Editorial
- Oxford University Press
- Citado
- 139 citas · más que el 98% de estudios similares · 7.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 25 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Nutrition and Health Studies
- Palabras clave
- vitamin D3 supplementation, vitamin D3, 25-hydroxyvitamin D, dose-response relationship, obesity, vitamin D deficiency, body size, hypercalciuria, hypercalcemia
- MeSH
- humans, vitamin d deficiency, obesity, calcium, cholecalciferol, calcifediol, parathyroid hormone, body mass index, cohort studies, single-blind method, seasons, kinetics, models, biological, dietary supplements, adult, middle aged, nebraska, female, male, recommended dietary allowances
4 autores
- Andjela Drincic🇺🇸 · autor de correspondenciaNebraska Medical Center; University of Nebraska Medical Center
- EE Fuller🇺🇸Creighton University; University of Nebraska Medical Center
- Robert P. Heaney🇺🇸Creighton University; University of Nebraska Medical Center
- Laura A. G. Armas🇺🇸Creighton University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Guidelines have suggested that obese adults need 2 to 3 times more vitamin D than lean adults to treat vitamin D deficiency, but few studies have evaluated the vitamin D dose response in obese subjects.
Objective
The purpose of this study was to characterize the pharmacokinetics of 25-hydroxyvitamin D [25(OH)D] response to 3 different doses of vitamin D₃ (cholecalciferol) in a group of obese subjects and to quantify the 25(OH)D dose-response relationship. DESIGN, SETTING, INTERVENTION, PATIENTS: This was a randomized, single-blind study of 3 doses of oral vitamin D₃ (1000, 5000, or 10,000 IU) given daily to 67 obese subjects for 21 weeks during the winter months.
Main outcome measures
Serum 25(OH)D levels were measured at baseline and after vitamin D replacement, and 25(OH)D pharmacokinetic parameters were determined, fitting the 25(OH)D concentrations to an exponential model.
Results
Mean measured increments in 25(OH)D at week 21 were 12.4 ± 9.7 ng/mL in the 1000 IU/d group, 27.8 ± 10.2 ng/mL in the 5000 IU/d group, and 48.1 ± 19.6 ng/mL in the 10,000 IU/d group. Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively. There were no hypercalcuria or hypercalcemia events during the study.
Conclusion
Our data show that in obese people, the 25(OH)D response to vitamin D₃ is directly related to dose and body size with ∼2.5 IU/kg required for every unit increment in 25(OH)D (nanograms per milliliter).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.